LONDON MARKET OPEN: Stocks start second half in green amid PMIs
(Alliance News) - European markets rose at Monday's open, kicking off the start of the second half on a positive note, boosted by strong trading in Asia and New York,
Read more(Alliance News) - European markets rose at Monday's open, kicking off the start of the second half on a positive note, boosted by strong trading in Asia and New York,
Read more(Alliance News) - AstraZeneca PLC and Tokyo-based partner Daiichi Sankyo Co Ltd on Monday announced that their investigational antibody drug conjugate Datopotamab deruxtecan showed positive results in an advanced non-small cell lung cancer trial.
Read more(Sharecast News) - AstraZeneca announced on Monday that datopotamab deruxtecan, or 'Dato-DXd', has shown promising results in a trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received at least one therapy.
Read moreAstraZeneca PLC - Cambridge-based pharmaceutical company - Announces USD400 million investment in global AZ Forest programme, aiming to plant 50 million trees by the end of 2025 and 200 million trees by 2030. Projects are in Brazil, India, Vietnam, Ghana and Rwanda. The programme is focused on reforestation, biodiversity and community resilience and spans over 100,000 hectares worldwide.
Read moreSTOXX 600 up 0.6%, techs among big gainers
*Read more(Alliance News) - AstraZeneca PLC on Tuesday said its Xigduo XR combination treatment has received approval in China for type-2 diabetes.
Read more(Alliance News) - AstraZeneca PLC on Monday said Soliris has been recommended for marketing authorisation in the EU for expanded use in generalised myasthenia gravis, gMG.
Read moreSignal included drugs from Eli Lilly, AstraZeneca, Sanofi
*Read moreCOPENHAGEN, June 22 (Reuters) - Novo Nordisk said on Thursday the European Union's drug watchdog had last month raised a thyroid cancer safety signal for several of its drugs including semaglutide, the active ingredient in its popular diabetes and obesity drugs, Ozempic and Wegovy.
Read moreOXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.
Read moreAstraZeneca down on report of China business spin off plan
*Read more(Alliance News) - The Financial Times reported on Monday that AstraZeneca PLC has drafted plans to separate its China business amid geopolitical tensions.
Read more(Sharecast News) - AstraZeneca has reportedly drawn up plans to break out its China business and list it separately in Hong Kong as a way to shelter the company against mounting geopolitical tensions.
Read more